GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Issuance of Debt

BIOYF (Biosyent) Issuance of Debt : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent Issuance of Debt?

Biosyent's Issuance of Debt for the three months ended in Dec. 2024 was $0.00 Mil.

Biosyent's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.


Biosyent Issuance of Debt Historical Data

The historical data trend for Biosyent's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Issuance of Debt Chart

Biosyent Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biosyent Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biosyent Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Biosyent's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

Biosyent Headlines

From GuruFocus

Q1 2022 Biosyent Inc Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

Q3 2019 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2022 Biosyent Inc Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

Q3 2020 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2019 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2020 Biosyent Inc Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

Q2 2022 Biosyent Inc Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

BioSyent Declares First Quarter 2025 Dividend

By GlobeNewswire 01-30-2025